...
首页> 外文期刊>Regulatory Toxicology and Pharmacology: RTP >Enzymatic extract from Ecklonia cava: Acute and subchronic oral toxicity and genotoxicity studies
【24h】

Enzymatic extract from Ecklonia cava: Acute and subchronic oral toxicity and genotoxicity studies

机译:来自Ecklonia cava的酶促提取物:急性和次级口腔毒性和遗传毒性研究

获取原文
获取原文并翻译 | 示例
           

摘要

Ecklonia cava (EC) is known to have antioxidant, anti-inflammatory, antidiabetic, and anticancer properties. Despite its wide use and beneficial properties, comprehensive toxicological information regarding EC extract is currently limited. Therefore, the purpose of this study was to investigate acute toxicity, subchronic toxicity, and genotoxicity of enzymatic EC extract according to test guidelines published by Organization for Economic Cooperation and Development. The acute oral LD50 values of this EC extract administered to rats and dogs were estimated to be more than 3000 mg/kg BW. In an oral 13-week toxicity study, changes in body weights of rats exposed to the EC extract up to 3000 mg/kg BW were found to be normal. In addition, repeated doses of EC extract failed to influence any systematic parameters of treatment-related toxic symptoms such as food/water consumption, mortality, urinalysis, hematology, serum biochemistry, organ weight, or histopathology. These results indicated that the no-observed-adverse-effect level for the EC extract was 3000 mg/kg/day for male and female rats. Data obtained from Ames test, chromosome aberration assay, and micronucleus assay indicated that EC extract was not mutagenic or clastogenic. Taken together, these results support the safety of enzymatic EC extract as a potential therapeutic for human consumption against various diseases.
机译:已知Ecklonia cava(EC)具有抗氧化剂,抗炎,抗糖尿病和抗癌性质。尽管使用和有益的特性,但目前有限有关EC提取物的综合毒理信息。因此,本研究的目的是根据经济合作与发展组织公布的测试指南,研究酶促毒性,副肾性毒性和酶促毒性。估计向大鼠和狗施用的EC提取物的急性口服LD50值估计超过3000mg / kg bw。在口服13周的毒性研究中,发现暴露于EC提取物的大鼠体重的变化,高达3000mg / kg BW是正常的。此外,重复剂量的EC提取物未能影响治疗相关的有毒症状的任何系统参数,例如食物/耗水,死亡率,尿症,血液学,血清生物化学,器官重量或组织病理学。这些结果表明EC提取物的无观察到的不良效应水平为男性和雌性大鼠的3000毫克/千克/天。从AMES测试,染色体像差测定和微核测定获得的数据表明EC提取物不是致突变的或裂殖的。总之,这些结果支持酶EC提取物作为人类消费对各种疾病的潜在治疗的安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号